ropinirole has been researched along with istradefylline in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carta, M; Cenci, MA; Fisone, G; Håkansson, K; Lundblad, M; Usiello, A | 1 |
| Jenner, P; Kanda, T; Kawai-Uchida, M; Mori, A; Okita, E; Soshiroda, K; Uchida, S | 2 |
3 other study(ies) available for ropinirole and istradefylline
| Article | Year |
|---|---|
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
Topics: Adenosine A2 Receptor Agonists; Adrenergic Agents; Amantadine; Animals; Antiparkinson Agents; Basal Ganglia; Buspirone; Disease Models, Animal; Disease Progression; Dopamine Agonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Indoles; Levodopa; Male; Mice; Mice, Inbred C57BL; Oxidopamine; Parkinsonian Disorders; Purines; Receptor, Adenosine A2A; Receptors, Dopamine D2; Reproducibility of Results; Riluzole; Treatment Outcome | 2005 |
The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Callithrix; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Synergism; Female; Indoles; Levodopa; Male; Motor Activity; Pergolide; Purines; Receptor, Adenosine A2A | 2015 |
The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Dopamine Agonists; Drug Therapy, Combination; Female; Indoles; Levodopa; Male; Motor Activity; MPTP Poisoning; Pergolide; Purines | 2015 |